surmount-1 trial tirzepatide weight loss results non-diabetic obesity Effect of in trial. (BMI: body mass index; CI: surmount-1 trial tirzepatide – Tirzepatide after intensive lifestyle intervention – Tirzepatide Weight Loss: Clinical Trial

Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims

The results showed that compared with placebo, tirpotide reduced the risk of heart failure events by 38% and reduced the risk of hospitalization due to heart failure by 56%

Oxidative stress and gut microbiota interplay exacerbates periodontitis in diabetic mice

Serotonin syndrome: Although uncommon with this specific combination, any increase in serotonin levels carries a small risk of this serious condition

Their therapeutic potential is evident in various disease contexts, including type 2 diabetes, neurodegenerative disorders, and inflammatory bowel disease (IBD)